Updated ACR guidelines for systemic juvenile idiopathic arthritis urge IL-1 receptor antagonists for all patients with synovitis and arthritis in five or more joints. Some may need glucocorticoid therapy as well.
How should rheumatologists respond to demands for medical marijuana, either from legislatures or directly from patients? Here from a knowledgeable source are 8 reasons (and more) why the medical and scientific evidence weighs heavily against it, especially in rheumatology.
Biosimilars, advances in treatment for rheumatoid and juvenile arthritis, numerous new guidelines and drug approvals. Review the past year's progress in rheumatology, as compiled by our Editorial Board.
The American College of Rheumatology has updated its guidelines for systemic juvenile idiopathic arthritis. All patients with synovitis and arthritis in 5 or more joints should start an IL-1 receptor antagonist, they say, and some may need glucocorticoid therapy as well.